GSK plc has reached settlements totaling up to $2.2 billion to resolve approximately 80,000 product liability cases related to its Zantac heartburn medication, which represent 93% of the lawsuits pending against the company in U.S. state courts. The settlements, which are contingent on eligibility criteria, are expected to be fully implemented by mid-2025, and GSK has not admitted liability in these cases. Additionally, GSK will pay $70 million to settle a separate qui tam complaint associated with Zantac, pending final approval from the Department of Justice. The company anticipates a charge of £1.8 billion ($2.3 billion) in its Q3 2024 earnings report due to these settlements, but maintains that its growth and R&D investment plans will remain unaffected. GSK asserts that scientific evidence does not substantiate claims that ranitidine, the active ingredient in Zantac, increases cancer risks. Following the announcement, GSK's stock rose by 7.68%.